JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level(324 views) Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia Morra V
Keywords: John Cunningham Virus, Antibodies, Multiple Sclerosis, Natalizumab, Polymerase Chain Reaction, Ultrasensitive C-Reactive Protein, C Reactive Protein, Immunosuppressive Agent, Virus Antibody, Virus Dna, Adult, Antibody Detection, Article, C Reactive Protein Blood Level, C Reactive Protein Urine Level, Cohort Analysis, Controlled Study, Enzyme Linked Immunospot Assay, False Negative Result, Female, Gene Dosage, Human, Jc Virus, Major Clinical Study, Observational Study, Protein Determination, Retrospective Study, Virus Reactivation,
Affiliations: *** IBB - CNR ***
Neurological Sciences Department, Federico II University, Naples, Italy.
Institute of Biostructure and Bioimaging, National Research Council, Federico II University, Naples, Italy.
Clinical Pathology Department, Federico II University, Naples, Italy.
References: Agostini, H.T., Ryschkewitsch, C.F., Singer, E.J., Stoner, G.L., Co-infection with two JC virus genotypes in brain, cerebrospinal fluid or urinary tract detected by direct cycle sequencing of PCR products (1996) J Neurovirol, 2 (4), pp. 259-26
Chesters, P.M., Heritage, J., McCance, D.J., Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues (1983) J Infect Dis, 147 (4), pp. 676-684
Heritage, J., Chesters, P.M., McCance, D.J., The persistence of papovavirus BK DNA sequences in normal human renal tissue (1981) J Med Virol, 8 (2), pp. 143-150
Pietropaolo, V., Videtta, M., Fioriti, D., Rearrangement patterns of JC virus noncoding control region from different biological samples (2003) J Neurovirol, 9 (6), pp. 603-611
Sunyaev, S.R., Lugovskoy, A., Simon, K., Gorelik, L., Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML) (2009) PLoS Genet, 5 (2)
Major, E.O., Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies (2010) Annu Rev Med, 61, pp. 35-47
Martin, S.I., Marty, F.M., Fiumara, K., Treon, S.P., Gribben, J.G., Baden, L.R., Infectious complications associated with alemtuzumab use for lymphoproliferative disorders (2006) Clin Infect Dis, 43 (1), pp. 16-24
Neff, R.T., Hurst, F.P., Falta, E.M., Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation (2008) Transplantation, 86 (10), pp. 1474-1478
Antonsson, A., Green, A.C., Mallitt, K.A., Prevalence and stability of antibodies to the BK and JC polyomaviruses: A long-term longitudinal study of Australians (2010) J Gen Virol, 91, pp. 1849-1853
Carter, J.J., Madeleine, M.M., Wipf, G.C., Lack of serologic evidence for prevalent simian virus 40 infection in humans (2003) J Natl Cancer Inst, 95 (20), pp. 1522-1530
Egli, A., Infanti, L., Dumoulin, A., Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors (2009) J Infect Dis, 199 (6), pp. 837-846
Engels, E.A., Rollison, D.E., Hartge, P., Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma (2005) Int J Cancer, 117 (6), pp. 1013-1019
Grabowski, M.K., Viscidi, R.P., Margolick, J.B., Jacobson, L.P., Shah, K.V., Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients (2009) J Med Virol, 81 (7), pp. 1140-1150
Kean, J.M., Rao, S., Wang, M., Garcea, R.L., Seroepidemiology of human polyomaviruses (2009) PLoS Pathog, 5 (3)
Knowles, W.A., Pipkin, P., Andrews, N., Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 (2003) J Med Virol, 71 (1), pp. 115-123
Matos, A., Duque, V., Beato, S., da Silva, J.P., Major, E., Meliço-Silvestre, A., Characterization of JC human polyomavirus infection in a Portuguese population (2010) J Med Virol, 82 (3), pp. 494-504
Padgett, B.L., Walker, D.L., Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy (1973) J Infect Dis, 127 (4), pp. 467-470
Rollison, D.E., Engels, E.A., Halsey, N.A., Shah, K.V., Viscidi, R.P., Helzlsouer, K.J., Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma (2006) Cancer Epidemiol Biomarkers Prev, 15 (3), pp. 543-550
Stolt, A., Sasnauskas, K., Koskela, P., Lehtinen, M., Dillner, J., Seroepidemiology of the human polyomaviruses (2003) J Gen Virol, 84, pp. 1499-1504
Verbeeck, J., Van Assche, G., Ryding, J., JC viral loads in patients with Crohn's disease treated with immunosuppression: Can we screen for elevated risk of progressive multifocal leukoencephalopathy (2008) Gut, 57 (10), pp. 1393-1397
Krumbholz, M., Meinl, I., Kümpfel, T., Hohlfeld, R., Meinl, E., Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis (2008) Neurology, 71 (17), pp. 1350-1354
Gorelik, L., Lerner, M., Bixler, S., Anti-JC virus antibodies: Implications for PML risk stratification (2010) Ann Neurol, 68 (3), pp. 295-303
Lee, P., Plavina, T., Castro, A., A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification (2013) J Clin Virol, 57 (2), pp. 141-146
Trampe, A.K., Hemmelmann, C., Stroet, A., Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort (2012) Neurology, 78 (22), pp. 1736-1742
Berger, J.R., Houff, S.A., Gurwell, J., Vega, N., Miller, C.S., Danaher, R.J., JC virus antibody status underestimates infection rates (2013) Ann Neurol, 74 (1), pp. 84-90
Rudick, R.A., O'Connor, P.W., Polman, C.H., Assessment of JC virus DNA in blood and urine from natalizumab-treated patients (2010) Ann Neurol, 68 (3), pp. 304-310
Laroni, A., Giacomazzi, C.G., Grimaldi, L., Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification (2012) J Neuroimmune Pharmacol, 7 (3), pp. 665-672
Ablij, H., Meinders, A., C-reactive protein: History and revival (2002) Eur J Intern Med, 13 (7), p. 412
Haddow, L.J., Dibben, O., Moosa, M.Y., Borrow, P., Easterbrook, P.J., Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome (2011) AIDS, 25 (9), pp. 1163-1174
Nixon, D.E., Landay, A.L., Biomarkers of immune dysfunction in HIV (2010) Curr Opin HIV AIDS, 5 (6), pp. 498-503
Narayanan, M., Szymanski, J., Slavcheva, E., BK virus associated renal cell carcinoma: Case presentation with optimized PCR and other diagnostic tests (2007) Am J Transplant, 7 (6), pp. 1666-1671
Landis, J.R., Koch, G.G., The measurement of observer agreement for categorical data (1977) Biometrics, 33 (1), pp. 159-174
Lanzillo, R., Liuzzi, R., Amato, L., JCV antibodies index on natalizumab treatment: Fluctuations and seroconversion (2013) Multiple Sclerosis Journal, 19
Bozic, C., Richman, S., Plavina, T., Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1 (2011) Ann Neurol, 70 (5), pp. 742-750
Olsson, T., Achiron, A., Alfredsson, L., Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort (2013) Mult Scler, 19 (11), pp. 1533-1538
Kitamura, T., Aso, Y., Kuniyoshi, N., Hara, K., Yogo, Y., High incidence of urinary JC virus excretion in nonimmunosuppressed older patients (1990) J Infect Dis, 161 (6), pp. 1128-1133
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J * Human IgG1 antibodies suppress angiogenesis in a target-independent manner(557 views) Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D. Impact Factor:0 ViewExport to BibTeXExport to EndNote
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(297 views) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 ViewExport to BibTeXExport to EndNote